ChronoScale (CHRN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Oct, 2026Executive summary
Supplement dated Oct. 16, 2026 updates director nominees and executive termination-related arrangements following the Sept. 30 Legacy Ekso disposition; the virtual annual meeting is Nov. 6, 2026.
Voting matters and shareholder proposals
Annual meeting proposals remain unchanged except Scott G. Davis is no longer standing for re-election; votes will be cast for the remaining nominees as instructed, not for Davis.
The Board recommends voting FOR each of the seven remaining nominees; directors elected will serve until the 2027 annual meeting and qualification of successors, or earlier resignation or removal.
Board of directors and corporate governance
Davis resigned effective Oct. 3, 2026; the revised slate comprises Wes Cummins, Ying Cenly Chen, Richard Nottenburg, Ella Benson, Douglas Miller, William M. Clancy and Andrew Schaap.
If all nominees are elected, seven directors will serve on the Board after the annual meeting.
Latest events from ChronoScale
- Revenue rose 148% as major AI deployments target $1B annualized run-rate.CHRN
Q3 2026 - A $500 million shelf backs cloud-focused growth and a conditional ~50 MW AI deployment plan.CHRN
Registration filing - Revenue fell 29% to $12.8M, net loss reached $11.7M, and a major business combination is pending.CHRN
Q4 2025 - Record Q4 revenue, improved margins, and narrowed net loss highlight strong operational progress.CHRN
Q4 2024 - Revenue fell 10% year-over-year, margins improved, but liquidity risks and funding needs remain.CHRN
Q1 2025 - Q2 revenue up 5%, margins improved, but going concern risk remains without new funding.CHRN
Q2 2024 - Q3 revenue dropped 10% YoY, net loss narrowed, and CMS reimbursement was achieved.CHRN
Q3 2024 - Q2 2025 revenue dropped 58% to $2.1M as Enterprise Health sales lagged, but Personal Health surged.CHRN
Q2 2025 - Q3 2025 revenue rose 2% YoY, gross margin hit 60.3%, and liquidity risks persist.CHRN
Q3 2025